Relmada Therapeutics (RLMD) shares continued falling on Thursday after some analysts downgraded its stock following failure in late-stage trial of anti-depressant candidate.
Mizuho downgraded the stock to neutral from outperform and slashed its price target to $1 from $23, while Leerink Partners lowered its rating to market perform from outperform, also with a $1 price target.
Relmada on Wednesday said that an independent data monitoring committee has determined that a late-stage study of REL-1017 as an adjunctive treatment for major depressive disorder is "futile." The company will determine its next steps after assessing the full dataset.
The company's stock was down nearly 16% in recent trading after falling more than 70% on Wednesday.
Price: 0.53, Change: -0.10, Percent Change: -15.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。